Clinical Trials and Research News Weekly Roundup | S2 E27 | Ivermectin VS Hydroxychloroquine

Jul 6, 2020 | Digital Media, Video, Weekly Roundup

Weekly roundup up

Ivermectin Study Reveals Fantastic Results: 100% of 60 Patients Better in an Average of Just Under 6 Days: Recently, TrialSite News reported on a study sponsored in Bangladesh by Upazila Health & Family Planning Officer’s (UHFPO) Office, and, First Affiliated Hospital Xi’an Jiaotong University. The observational study was conducted from May 2 to June 5, 2020. The principal investigators observed 181 patients who tested positive for COVID-19. The Research team recently shared the results via preprint server and ResearchGate. The study team concluded that concerning the treatment outcome, adverse effect, and safety, the Ivermectin and Doxycycline combination was superior to the use of Hydroxychloroquine and Azithromycin therapy in the case of mild to moderate degree of COVID-19 patients. Although both treatment regimens were observed to be effective for this study, the Ivermectin treatment was superior.…

President of Dominican Republic’s Largest Private Health Group Discusses the Success of Ivermectin as a Treatment for Early Stage COVID-19: The Rescue Group (Grupo Rescue) is a leading national private health network in the Caribbean nation of Dominican Republic. The Rescue Group operates three hospitals, including Punta Cana Medical Center, Bournigal Medical Center and Canela Clinic as well as affiliated referral hospitals, urgent care facilities, and an in-home service in addition to 17 emergency hotel medical centers. José Natalio Redondo, the group’s president, is renowned in Latin America for the incredible success of his Ivermectin protocol used at the Rescue Group hospitals. Dr. Redondo took the time to speak with TrialSite News about the success of the Ivermectin treatment: they have treated 1,300 early stage COVID-19 patients and have observed dramatic results.…

Dr. José Natalio Redondo Contact Email: National University Singapore Launches Large COVID-19 Prophylaxis Study Targeting Ivermectin & HCQ: The National University of Singapore serves the island nation as a tertiary hospital, clinical training center, and research center for medical and dental faculties. With 1,160 beds serving more than 670,000 outpatients and 49,000 inpatients, NUS is ranked first in Singapore & Asia Pacific and 11th in the world, according to the 2019 QA World University Rankings. This prestigious research organization initiated a large randomized Phase III open-label prophylaxis trial among migrant workers at high-risk of COVID-19; this study is known as the DORM Trial. Among the prophylaxis under investigation, hydroxychloroquine and Ivermectin are included. The study is led by Senior Consultant, Division of Neurology, Department of Medicine at NUS, Associate professor Seet Chee Seong Raymond.……

First Phytopharmaceutical Drug Approved for Clinical Trials targeting COVID-19 in India: Sun Pharmaceuticals, an India pharmaceutical company, initiated a Phase 2 clinical trial to investigate AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19 cases. 12 research sites in India will evaluate the drug on 210 COVID-19 patients for what will be a treatment duration of 10 days. This is the first time a phytopharmaceutical drug has been approved for a clinical trial by the Drugs Controller General of India (DCGI) for COVID-19.


  1. John F Backus

    Thank you for continuing to spread the real news that safe and cost effective treatments, such as with the use of ivermectin, exist and are very successful.

    Shame upon the other news organizations and the medical institutions that ignore this and which promote new treatments which typically server there own financial interests.

    I hope that in the future a class-action lawsuit is made against the big organizations that are ignoring these treatments to the detriment of the lives and health (current and future) of so many human beings.

    Keep sharing these things.

    • Darci kite

      Could something like mobic which has been proven a good product and never been recalled and is cheap work with ivermectine and doxycyline.

Pin It on Pinterest